Correlation Between Lumos Pharma and Marker Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lumos Pharma and Marker Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lumos Pharma and Marker Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lumos Pharma and Marker Therapeutics, you can compare the effects of market volatilities on Lumos Pharma and Marker Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lumos Pharma with a short position of Marker Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lumos Pharma and Marker Therapeutics.

Diversification Opportunities for Lumos Pharma and Marker Therapeutics

0.66
  Correlation Coefficient

Poor diversification

The 3 months correlation between Lumos and Marker is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding Lumos Pharma and Marker Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Marker Therapeutics and Lumos Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lumos Pharma are associated (or correlated) with Marker Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Marker Therapeutics has no effect on the direction of Lumos Pharma i.e., Lumos Pharma and Marker Therapeutics go up and down completely randomly.

Pair Corralation between Lumos Pharma and Marker Therapeutics

Given the investment horizon of 90 days Lumos Pharma is expected to generate 0.81 times more return on investment than Marker Therapeutics. However, Lumos Pharma is 1.23 times less risky than Marker Therapeutics. It trades about 0.12 of its potential returns per unit of risk. Marker Therapeutics is currently generating about 0.01 per unit of risk. If you would invest  225.00  in Lumos Pharma on August 29, 2024 and sell it today you would earn a total of  205.00  from holding Lumos Pharma or generate 91.11% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Lumos Pharma  vs.  Marker Therapeutics

 Performance 
       Timeline  
Lumos Pharma 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Lumos Pharma are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak primary indicators, Lumos Pharma displayed solid returns over the last few months and may actually be approaching a breakup point.
Marker Therapeutics 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Marker Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating forward-looking signals, Marker Therapeutics may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Lumos Pharma and Marker Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lumos Pharma and Marker Therapeutics

The main advantage of trading using opposite Lumos Pharma and Marker Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lumos Pharma position performs unexpectedly, Marker Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marker Therapeutics will offset losses from the drop in Marker Therapeutics' long position.
The idea behind Lumos Pharma and Marker Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Complementary Tools

Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
FinTech Suite
Use AI to screen and filter profitable investment opportunities